Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vesigen Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is overseen by 1 distinct examiner and 1 distinct art unit, representing a singular point of review for the company. This concentration indicates that the company's immediate legal efforts are focused on a specific biological innovation. The pending office action is the only active case currently under review for this portfolio.
The busiest examiner for the portfolio is VU, JAKE MINH, who handles 1 busiest examiner pending office action. The company's immediate prosecution results are tied to the specific feedback from this official. For a practitioner, it is important to tailor arguments to the specific preferences of this official within the Biotechnology & Pharmaceuticals art unit. The success of the 1 pending office action will be a key indicator of the company's ability to protect its innovations in this sector. Addressing the specific technical concerns of this examiner is essential for the company's near-term patent goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009290 | ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM | VU, JAKE MINH | 52d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009290 | ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM | VU, JAKE MINH | 52d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009290 | ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM | VU, JAKE MINH | 1618 | §102§103§112Other | Final Rejection | 52d overdue | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial